FDA
-
-
-
-
-
-
-
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
-
-
-
-
-
-
-
Mezzion Pharma's new orphan drug udenafil improved ventricular function measured by myocardial performance index (MPI) in adolescents with congenital single ventricle heart disease (SVHD) - Furth
-
-
-
-
325,596 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

